2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Levodopa Induced Dyskinesia (LID): new trials by email Literature Review of Levodopa Induced Dyskinesia (LID) trials Research Report on Levodopa Induced Dyskinesia (LID)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID amantadine HCl ER, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 3 | Terminated | Adamas Pharmaceuticals, Inc. | 135 | 2014-07-30 | 2022-02-16 |
| Open-Label Safety Study of ADS-5102 in PD Patients With LID ADS-5102 - Dyskinesia, Levodopa Induced Dyskinesia (LID) | Phase 3 | Completed | Adamas Pharmaceuticals, Inc. | 223 | 2014-07-01 | 2020-10-06 |
| ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) ADS-5102, Placebo - Dyskinesia, Levodopa Induced Dyskinesia (LID) | Phase 3 | Completed | Adamas Pharmaceuticals, Inc. | 126 | 2014-05-01 | 2018-02-06 |
Dyskinesias (3) · Parkinson Disease (3) · Parkinsonian Disorders (3)
Basal Ganglia Diseases (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Movement Disorders (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Synucleinopathies (3)
Amantadine (1)
Adamas Pharmaceuticals, Inc. (3)
Canada (3) · United States (3) · France (2) · Germany (2) · Spain (2) · Austria (1)
PMID 28604926, PMID 28777755, PMID 29532440, PMID 33864229, PMID 34024025